Provided in the present disclosure is an antibody or an antigen-binding fragment thereof that binds to the respiratory syncytial virus F protein. Further provided in the present disclosure is the use of the antibody or the antigen-binding fragment thereof in the preparation of a drug for the treatment and/or prevention of RSV infections.

The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.

The present invention provides a chromatographic analysis device capable of increasing the detection sensitivity to a detection target while suppressing a nonspecific reaction. The present invention relates to a chromatographic analysis device which includes at least a chromatographic medium part (3) on which a detection part (4) for detecting a detection target contained in an analyte is supported, wherein the chromatographic medium part (3) has a structure in which a membrane is provided on a support, the average film thickness of the membrane is from 110 m to 130 m, and the developing flow rate of the membrane is from 30 to 45 sec/40 mm.

The present invention describes a liquid direct fluorescence antibody assay that is rapid and sensitive to detect respiratory virus in infected cells. The assay includes centrifugation of the specimen, incubation of sample and reagents in solution, and detection of the absence or presence of respiratory virus. Sapogenin is used as a detergent to permeabilize the cells for entry of the monoclonal antibodies to react with intracellular antigens. The cells are stained with fluorescently labeled monoclonal antibodies against the viral antigens along with a background stain and a fluorescent nuclear stain. This counter staining decreases background and allows co-localization of antigen and nuclear structures for enhanced detection.

The disclosure provides isolated antibodies and antigen-binding fragments that bind to the G protein of RSV and which are capable of neutralizing RSV.

The present invention relates to an ultrasensitive rapid antigen detection kit for detecting N protein from SARS-CoV-2 virus in a sample, and methods for detecting N protein. The kit includes a sample collector, a collection and enrichment tube and a rapid antigen detection component with a test strip. The collection and enrichment tube contains a first part containing lyophilized ATPS reagents and a second part containing a lysis buffer. The sample is mixed with the lyophilized ATPS reagents and the lysis buffer to form a mixture. The enrichment is realized by concentrating the target analyte into one of the two phases formed by ATPS.

Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.

The present application relates to a erythrocyte-derived magnetic immune particle and uses thereof, according to an aspect, the erythrocyte-derived magnetic immune particle include an erythrocyte-derived cell membrane, which may minimize in vivo side effect, and may be used to detect and remove various type of substances (for example, a pathogenic substance, an inflammatory cytokine, blood glucose, a cancer-related substance, and a brain disease-related substance, etc.) from a sample with excellent efficiency, which may be useful for diagnosing, preventing, or treating various type of diseases, including an infectious disease, an inflammatory disease, diabetes, cancer, and brain disease.

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

The invention relates to a DDX3X inhibitor for use in the treatment of pneumovirus infection in a mammal, wherein the DDX3X inhibitor may be a compound of Formula (I) wherein y, Z, R.sup.1, X, L, R.sup.a and R.sup.b are as defined herein. The invention also relates to compounds of Formula (I). ##STR00001##